Jinchao

Jinchao Hunag, Markham CA

Patent application number	Description	Published
20090063210	ORGANIZATIONAL DESIGN APPROACH TO TRANSITION COST ASSESSMENT FOR BUSINESS TRANSFORMATION - A method for facilitating in assessing transitional costs in business transformations using a computer-aided organizational design system is provided. The method comprises creating a first organization design model representative of the current organizational design state of an organization using a graphical tool. The method further comprises changing the first organization design model into a second organization design model representative of the organizational design state of the organization after the business transformation. The method further comprises generating a report identifying the transition cost factors and the transition cost of moving from the first organization design model to the second organization design model, wherein the transition cost is determined based on predetermined calculation algorithms or heuristics.	03-05-2009

Patent application number	Description	Published
20080222450	Zero-penalty RAID controller memory leak detection and isolation method and system utilizing sequence numbers - A method and system for detecting and isolating memory leak in RAID controllers utilizing sequence numbers. The system monitors whether the count of un-freed memory blocks for a sequence number (SN) zone (after a start-of-day SOD operation, but smaller than the current sequence number zone) is not eventually decremented to zero. The memory leak can be detected when un-freed memory blocks exist and follow a similar pattern with respect to all other adjacent SN zones. The detected memory leak can be isolated utilizing shell commands, task information, caller information, sequence number, memory allocation size and a pointer to the next allocated memory block.	09-11-2008

Patent application number	Description	Published
20110052606	Humanized Anti-Human NKG2A Monoclonal Antibody - The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.	03-03-2011